Amongst continuous research studies work to combat several cancer cells' resistance via circumvention of diverse kinases, including FLT3, PDGFRα, VEGFR-2 (KDR), and Aurora A and B; in 2021, El-Hussieny et al. stated compound 18 that afforded versatile tyrosine kinases' inhibitory activity including PDGFRα, and FLT3 that are fundamental for remedy of various leukemia kinds with IC50 equal to 24.15 nM meaningfully less than Sunitinib IC50 value equal to 58.93 nM, and IC50 equal to 74.85 nM less than Sunitinib IC50 value of 38.8 nM, respectively (Table 3) [88]. This evidence concerns the gene FLT3 and leukemia.